DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.

Analysts predict sales of Dato-DXd could hit $5.9 billion in 2030, but the antibody-drug conjugate faced a series of setbacks ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

AstraZeneca's Datroway gains FDA approval for HR-positive, HER2-negative breast cancer after prior therapies, based on Phase ...

After Lung Cancer Approval, AstraZeneca's Imfinzi Goes Under FDA Priority Review For Bladder Cancer AstraZeneca's Imfinzi gains FDA Priority Review for bladder cancer. Key trial data shows ...

T-DXd outperformed physician’s choice of chemotherapy regardless of patients’ disease burden or time to progression on prior therapy.

Four of the top 10 drugs by prescription sales in 2025 will be from the new incretin class, according to the latest analysis by Evaluate. Consensus forecasts for Ozempic, Wegovy, Mounjaro and Zepbound ...

The clearance of Datroway comes months after the companies narrowed approval plans in lung cancer and opens up a market ...

AstraZeneca (AZN) has overhauled its local management in China in a bid to move on from recent scandals and revive sales after the arrest of ...

CIII nasal spray, marking the first monotherapy to be approved for adults with treatment-resistant depression (TRD).

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...